J 2018

Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery

STANÍK, Michal, Alexandr POPRACH, D. MACIK, I. CAPAK, Denisa KREJČÍ et. al.

Základní údaje

Originální název

Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery

Autoři

STANÍK, Michal (703 Slovensko, garant), Alexandr POPRACH (203 Česká republika), D. MACIK (203 Česká republika), I. CAPAK (203 Česká republika), Denisa KREJČÍ (203 Česká republika, domácí), N. MARECKOVA (203 Česká republika), Radek LAKOMÝ (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí) a Jan DOLEŽEL (203 Česká republika)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2018, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.771

Kód RIV

RIV/00216224:14110/18:00104048

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000435149800016

Klíčová slova anglicky

urinary bladder neoplasms; lymphadenopathy; combined modality therapy; induction chemotherapy; cystectomy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 21:39, Soňa Böhmová

Anotace

V originále

Patients with clinically node-positive bladder cancer have a poor prognosis, with many receiving only palliative chemotherapy. We evaluated oncological results in bladder cancer patients with clinically regional and supraregional lymphadenopathy treated with induction chemotherapy (IC) and consolidative cystectomy. Twenty-five patients with clinically node-positive bladder cancer (including pelvic and retroperitoneal nodes) were treated with 2-4 cycles of IC followed by consolidative cystectomy between 2010 and 2016. Pathologic complete response (pCR) was defined as no residual tumor in the final specimen (ypT0N0). The 3-year cancer-specific (CSS) and recurrence-free survival (RFS) for the whole cohort were 52% and 39%, respectively. The 3-year RFS differed according to volume of nodal metastases, the rates were 56% for minimal nodal disease (cN1) versus 33% for cN2-3 and 0% for cM1 disease (p<0.001). pCR was seen in 7 (28%) patients; 50% in cN1 versus 13% in cN3-M1. pCR associated with 3-year CSS of 80% versus 45% in patients with persistent disease aft er IC. In conclusion, a multimodal approach to patients with clinically node-positive bladder cancer, consisting of IC followed by consolidative surgery, may achieve long-term survival in selected patients. Better results may be expected in patients with initially minimal nodal burden and complete pathologic response to chemotherapy. Further studies are warranted to improve patient selection for consolidative surgery, especially with supra-regional metastases.